Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epato is a veterinary nutritional supplement developed by Nextmune for hepatic support in companion animals, specifically dogs and cats. Formulated as a dietetic complementary feed, it is intended to support liver function during chronic liver failure, food-related stress, or drug therapies that may induce hepatotoxicity. Its primary active components include silymarin (derived from milk thistle), which promotes hepatocyte regeneration and detoxification, and phosphatidylcholine, which enhances the intestinal absorption of silymarin and helps maintain the integrity of cell membranes. The formulation is further enriched with Vitamin E and B complex vitamins to provide antioxidant support and metabolic assistance. Epato is available in oral tablet and paste forms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Epato.